Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Autoimmunity Reviews

Volumn 12, Issue 8, 2013, Pages 854-859

  Kattah, Andrea G ^a   Fervenza, Fernando C ^a   Roccatello, Dario ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

ANCA; Focal segmental glomerulosclerosis; Lupus nephritis; Membranous nephropathy; Minimal change disease; Mixed cryoglobulinemia; Rituximab; Vasculitis

Indexed keywords

ALPHA 1 MICROGLOBULIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RETINOL BINDING PROTEIN; RITUXIMAB; STEROID;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CONGENITAL NEPHROTIC SYNDROME; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOCAL GLOMERULOSCLEROSIS; FOOD AND DRUG ADMINISTRATION; GLOMERULOPATHY; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SLEDAI; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES;

EID: 84878577565     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.09.002     Document Type: Review

References (96)

1. Eisenberg R., Looney R.J. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol 2005, 117(3):207-213.
2. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003, 171(3):1581-1587.
3. Cheifetz A., Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005, 72(4):250-256.
4. Martin F., Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006, 24:467-496.
5. Genovese M., E.P., Ruderman E., et al. Immunoglobulin levels and infection rates in patients with rheumatoid arthritis (RA) treated with repeated courses of rituximab. Arthritis Rheum 2007, 56:S14.
6. Gea-Banacloche J.C. Rituximab-associated infections. Semin Hematol 2010, 47(2):187-198.
7. Radice A., Bianchi L., Sinico R.A. Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev Aug 17 2012.
8. Fabrizi F., Lunghi G., Messa P., Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008, 21(6):813-825.
9. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361(1):11-21.
10. Pons-Estel G.J., Serrano R., Plasín M.A., et al. Epidemiology and management of refractory lupus nephritis. Autoimmun Rev Sep 2011, 10(11):655-663. [Epub 2011 May 1. Review]. 10.1016/j.autrev.2011.04.032.
11. Lepse N., Abdulahad W.H., Kallenberg C.G., Heeringa P. Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev Dec 2011, 11(2):77-83. [Epub 2011 Aug 11. Review].
12. Rutgers A., Kallenberg C.G. Refractory vasculitis. Autoimmun Rev Sep 2011, 10(11):702-706. [Epub 2011 May 11. Review]. 10.1016/j.autrev.2011.04.024.
13. Sinico R.A., Di Toma L., Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev Aug 16 2012.
14. Gómez-Puerta J.A., Quintana L.F., Stone J.H., et al. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev Jul 2012, 11(9):646-652. [Epub 2011 Nov 21].
15. Specks U., Fervenza F.C., et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44(12):2836-2840.
16. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257(6):540-548.
17. Gottenberg J.E., Guillevin L., Lambotte O., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64(6):913-920.
18. Omdal R., Wildhagen K., Hansen T., et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005, 34(3):229-232.
19. Bosch X., Guilabert A., et al. Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?. Trends Immunol 2008, 29(6):280-289.
20. Jones R.B., Ferraro A.J., Chaudhry A.N., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60(7):2156-2168.
21. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220.
22. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
23. Specks U.f.t.R.-I.R.G. Long-term efficacy and safety results of the RAVE trial. Clin Exp Immunol 2011, (164):65.
24. Roccatello D., Sciascia S., Rossi D., et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 2011, 34(2):175-180.
25. Smith R.M., Jones R.B., Guerry M.J., et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012.
26. Cartin-Ceba R., Golbin J.M., Keogh K.A., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): A single-center ten-year experience. Arthritis Rheum 2012.
27. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50(8):2580-2589.
28. Leandro M.J., Cambridge G., Edwards J.C., et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44(12):1542-1545.
29. Marks S.D., Patey S., Brogan P.A., et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005, 52(10):3168-3174.
30. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006, 54(9):2970-2982.
31. Merrill J.T., Neuwelt C.M., Wallace D.J., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62(1):222-233.
32. Rovin B.H., Furie R., Latinis K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64(4):1215-1226.
33. Lu T.Y., Ng K.P., Cambridge G., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61(4):482-487.
34. Gunnarsson I., Sundelin B., Jónsdóttir T., et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007, 56(4):1263-1272.
35. Díaz-Lagares C., Croca S., Sangle S., et al. UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev Mar 2012, 11(5):357-364. [Epub 2011 Oct 18].
36. Roccatello D., Sciascia S., Rossi D., et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011, 26(12):3987-3992.
37. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101(10):3827-3834.
38. Sansonno D., De Re V., Lauletta G., et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003, 101(10):3818-3826.
39. Roccatello D., Baldovino S., Rossi D., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004, 19(12):3054-3061.
40. Visentini M., Ludovisi S., Petrarca A., et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011, 10(11):714-719.
41. Pekow J., Chung R.T. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol 2006, 40(5):450.
42. Basse G., Ribes D., Kamar N., et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005, 80(11):1560-1564.
43. Ferri C., Cacoub P., Mazzaro C., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11(1):48-55.
44. Terrier B., Saadoun D., Sène D., et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009, 60(8):2531-2540.
45. Bestard O., Cruzado J.M., Ercilla G., et al. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 2006, 21(8):2320-2324.
46. Evans J.T., Shepard M.M., Oates J.C., et al. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol 2008, 42(7):862-863.
47. Korte M.R., Fieren M.W., Sampimon D.E., et al. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia. Neth J Med 2008, 66(1):27-30.
48. Massari M., Catania A., Magnani G. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. Dig Liver Dis 2007, 39(SUPPL. 1):S134-S135.
49. Petrarca A., Rigacci L., Monti M., et al. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis 2007, 39(SUPPL. 1):S129-S133.
50. Cavallo R., Roccatello D., Menegatti E., et al. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009, 256(7):1076-1082.
51. Uppal R., Charles E., Lake-Bakaar G. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab. J Clin Virol 2010, 47(1):69-71.
52. Saadoun D., Rosenzwajg M., Landau D., et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008, 111(11):5334-5341.
53. Quartuccio L., Salvin S., Fabris M., et al. Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. Ann Rheum Dis 2008, 67(10):1494-1495.
54. De Vita S., Quartuccio L., Isola M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64(3):843-853.
55. Sene D., Ghillani-Dalbin P., Amoura Z., et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60(12):3848-3855.
56. Saadoun D., Resche-Rigon M., Sene D., et al. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008, 67(10):1431-1436.
57. Sansonno D., Tucci F.A., Montrone M., et al. B-cell depletion in the treatment of mixed cryoglobulinemia. Dig Liver Dis 2007, 39(SUPPL. 1):S116-S121.
58. Pietrogrande M., De Vita S., Zignego A.L., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10(8):444-454.
59. Dammacco F., Tucci F.A., Lauletta G., et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010, 116(3):343-353.
60. Roccatello D., Baldovino S., Rossi D., et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008, 34(1):111-117.
61. Cattran D.C. Membranous nephropathy: quo vadis?. Kidney Int 2002, 61(1):349-350.
62. Remuzzi G., Chiurchiu C., Abbate M., et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002, 360(9337):923-924.
63. Fervenza F.C., Cosio F.G., Erickson S.B., et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008, 73(1):117-125.
64. Fervenza F.C., Abraham R.S., Erickson S.B., et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010, 5(12):2188-2198.
65. Ruggenenti P, Cravedi P, Narasa M, Ruggiero B, Chianca A, Remuzzi G, Effects of Rituximab in 100 consecutive patients with idiopathic membranous nephropathy and nephrotic syndrome despite RAS inhibition. J Am Soc Nephrol in press.
66. Beck L.H., Fervenza F.C., Beck D.M., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22(8):1543-1550.
67. Debiec H., Guigonis V., Mougenot B., et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002, 346(26):2053-2060.
68. Prunotto M., Carnevali M.L., Candiano G., et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010, 21(3):507-519.
69. Bruschi M., Carnevali M.L., Murtas C., et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics 2011, 74(10):2008-2017.
70. Murtas C., Bruschi M., Carnevali M.L., et al. In vivo characterization of renal auto-antigens involved in human auto-immune diseases: the case of membranous glomerulonephritis. Proteomics Clin Appl 2011, 5(1-2):90-97.
71. Murtas C., Bruschi M., Candiano G., et al. Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy. Clin J Am Soc Nephrol 2012.
72. Reichert L.J., Koene R.A., Wetzels J.F. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol 1997, 48(2):79-84.
73. Bazzi C., Petrini C., Rizza V., et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002, 17(11):1890-1896.
74. Branten A.J., du Buf-Vereijken P.W., Klasen I.S., et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005, 16(1):169-174.
75. Hofstra J.M., Deegens J.K., Willems H.L., Wetzels J.F. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. Nephrol Dial Transplant 2008, 23(8):2546-2551.
76. Bazzi C., Petrini C., Rizza V., et al. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis 2001, 38(2):240-248.
77. Irazabal MV, Eirin A, Lieske J, Beck LH, Borlad TM, Dillon JJ, et al., Low and high molecular weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant in press.
78. Shalhoub R.J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974, 2(7880):556-560.
79. Ali A.A., Wilson E., Moorhead J.F., et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment?. Transplantation 1994, 58(7):849-852.
80. Wei C., El Hindi S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17(8):952-960.
81. Benz K., Dötsch J., Rascher W., Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004, 19(7):794-797.
82. Pescovitz M.D., Book B.K., Sidner R.A. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006, 354(18):1961-1963.
83. Gilbert R.D., Hulse E., Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006, 21(11):1698-1700.
84. Fujinaga S., Hirano D., Nishizaki N., et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010, 25(3):539-544.
85. Ravani P., Magnasco A., Edefonti A., et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011, 6(6):1308-1315.
86. Magnasco A., Ravani P., Edefonti A., et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012, 23(6):1117-1124.
87. François H., Daugas E., Bensman A., Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 2007, 49(1):158-161.
88. Sawara Y., Itabashi M., Kojima C., et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 2009, 72(1):69-72.
89. Hoxha E., Stahl R.A., Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011, 76(2):151-158.
90. Kisner T., Burst V., Teschner S., et al. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. Nephron Clin Pract 2012, 120(2):c79-c85.
91. Fernandez-Fresnedo G., Segarra A., González E., et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009, 4(8):1317-1323.
92. Ochi A., Takei T., Nakayama K., et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med 2012, 51(7):759-762.
93. Bayrakci U.S., Baskin E., Sakalli H., et al. Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant 2009, 13(2):240-243.
94. Sakai K., Takasu J., Nihei H., et al. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant 2010, 24(SUPPL. 22):60-65.
95. Ponticelli C., Glassock R.J. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010, 5(12):2363-2372.
96. Fornoni A., Sageshima J., Wei C., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011, 3(85):85ra46.